Comparison of Abbott ID Now, DiaSorin Simplexa, and CDC FDA Emergency Use Authorization Methods for the Detection of SARS-CoV-2 from Nasopharyngeal and Nasal Swabs from individuals Diagnosed with COVID-19

Authors

Daniel D. Rhoads, Case Western Reserve UniversityFollow
Sree S. Cherian, Case Western Reserve UniversityFollow
Lisa M. Stempak, Case Western Reserve UniversityFollow
Christine L. Schmotzer, Case Western Reserve UniversityFollow
Navid Sadri, Case Western Reserve UniversityFollow

Author ORCID Identifier

Daniel D. Rhoads

Navid Sadri

Document Type

Letter to the Editor

Publication Date

7-23-2020

Keywords

COVID-19 (disease), communicable diseases, coronavirus infections, nucleic acid amplification, SARS-CoV-2, coronavirus, emergency use authorization, in vitro diagnostic, virology

Publication Title

Journal of Clinical Microbiology

Rights

© 2020 Rhoads et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Recommended Citation

Rhoads DD, Cherian SS, Roman K, Stempak LM, Schmotzer CL, Sadri N. 2020. Comparison of Abbott ID Now, DiaSorin Simplexa, and CDC FDA emergency use authorization methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from individuals diagnosed with COVID19. J Clin Microbiol 58:e00760-20. https://doi .org/10.1128/JCM.00760-20.